Table 3.
Bleeding outcomes
| Outcome | Rivaroxaban N = 32,078 # of events (%/year) |
Warfarin N = 83,971 # of events (%/year) |
PS overlap weighted HR (95%CI) |
|---|---|---|---|
| Hospitalization for major or CRNM bleed | 1989 (2.17) | 5542 (2.31) | 0.94 (0.89–0.99) |
| Major or CRNM bleed | 6416 (6.95) | 16,710 (6.95) | 1.00 (0.97–1.03) |
| Major bleed | 834 (0.90) | 2687 (1.11) | 0.80 (0.74–0.97) |
| Critical organ bleed | 321 (0.35) | 1344 (0.54) | 0.63 (0.55–0.72) |
| Intracranial hemorrhage | 257 (0.29) | 1008 (0.40) | 0.72 (0.62–0.84) |
| Extracranial bleed | 1732 (1.87) | 4450 (1.86) | 1.00 (0.95–1.07) |
| CRNM bleed | 5614 (6.09) | 14,443 (6.00) | 1.02 (0.98–1.05) |
CI confidence interval, CRNM clinically relevant non-major, HR hazard ratio, ICH intracranial hemorrhage, ISTH International Society of Thrombosis and Haemostasis, PS propensity score